Literature DB >> 14644399

Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects.

Natalie Fournier1, Omar Francone, George Rothblat, Dominique Goudouneche, Michèle Cambillau, Ginny Kellner-Weibel, Peggy Robinet, Lori Royer, Nicole Moatti, Alain Simon, Jean-Louis Paul.   

Abstract

Since elevated plasma triglycerides (TGs) are an independent cardiovascular risk factor, we have compared the cholesterol efflux potential of sera from asymptomatic hypertriglyceridemic (HTG) type IIb, type IV or normolipidemic (NLP) individuals using two different cell systems. In both type IIb and IV HTG, the efflux of cholesterol from SR-BI-rich Fu5AH cells was similar to that obtained with NLP. The maintenance of efflux efficiency in spite of reduced HDL-cholesterol levels can be mainly attributed to the relative enrichment of HDL with phospholipid. In the J774 macrophage cell system, pretreatment with cAMP, which upregulates ABCA1, induced a markedly higher increase in efflux to type IV sera compared with type IIb or NLP. In addition, type IV sera exhibited two-fold higher pre-beta HDL relative concentration (percentage of total apo AI) compared with NLP. Moreover, positive correlations were established between ABCA1-mediated efflux and the serum pre-beta HDL levels or TG concentrations. Thus, the hyperTGemia is associated with a higher fraction of apo AI recovered as pre-beta HDL which appear to be partly responsible for enhanced efflux obtained upon the cAMP stimulation of J774 cells. In conclusion, we demonstrated for the first time that the ABCA1-expressing J774 cell system is responsive to the percent of apo AI present in human serum as pre-beta HDL. Our results suggest that high-plasma TG, accompanied by low HDL may not result in an impaired cholesterol efflux capacity. Copyright 2003 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644399     DOI: 10.1016/j.atherosclerosis.2003.08.011

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

1.  Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes.

Authors:  Hussein N Yassine; Alexandra Belopolskaya; Christina Schall; Craig S Stump; Serrine S Lau; Peter D Reaven
Journal:  Metabolism       Date:  2014-03-05       Impact factor: 8.694

2.  Accumulation and expression of serum amyloid P component in human atherosclerotic lesions.

Authors:  Zhiqing Song; Lei Cai; Ling Guo; Yoshitane Tsukamoto; Chikao Yutani; Xiang-An Li
Journal:  Atherosclerosis       Date:  2010-02-06       Impact factor: 5.162

3.  Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome.

Authors:  Madhuri Vasudevan; Urbain Tchoua; Baiba K Gillard; Peter H Jones; Christie M Ballantyne; Henry J Pownall
Journal:  J Clin Lipidol       Date:  2013-05-25       Impact factor: 4.766

4.  Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.

Authors:  Jose Castro-Perez; François Briand; Karen Gagen; Sheng-Ping Wang; Ying Chen; David G McLaren; Vinit Shah; Rob J Vreeken; Thomas Hankemeier; Thierry Sulpice; Thomas P Roddy; Brian K Hubbard; Douglas G Johns
Journal:  J Lipid Res       Date:  2011-08-14       Impact factor: 5.922

5.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

6.  Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia.

Authors:  Michael H Davidson
Journal:  EBioMedicine       Date:  2015-03-09       Impact factor: 8.143

Review 7.  Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida
Journal:  Int J Mol Sci       Date:  2019-03-08       Impact factor: 5.923

Review 8.  High-Density Lipoprotein Function and Dysfunction in Health and Disease.

Authors:  Scott T Chiesa; Marietta Charakida
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

9.  Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity.

Authors:  Andrea L Koekemoer; Veryan Codd; Nicholas G D Masca; Christopher P Nelson; Muntaser D Musameh; Bernhard M Kaess; Christian Hengstenberg; Daniel J Rader; Nilesh J Samani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-31       Impact factor: 8.311

10.  Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response.

Authors:  Alexandre Motte Motte; Julie Gall Gall; Joe-Elie Salem; Eric Dasque; Martine Lebot; Eric Frisdal; Sophie Galier; Elise F Villard; Elodie Bouaziz-Amar; Jean-Marc Lacorte; Beny Charbit; Wilfried Le Goff; Philippe Lesnik; Maryse Guerin
Journal:  Biomolecules       Date:  2020-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.